amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
![Amicus Therapeutics logo](/files/LOGO/1178879-FOLD.png)
Company profile
Ticker
FOLD
Exchange
Website
CEO
John Crowley
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AMICUS THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
1.Callidus Biopharma, Inc. • 2.Celenex, Inc. • 3.Scioderm, Inc. • 4.MiaMed, Inc. • 5.Amicus Therapeutics International Holding Limited • 6.Amicus Therapeutics UK Limited • 7.Amicus Therapeutics UK Operations Limited • 8.Amicus Therapeutics SAS • 9.Amicus Therapeutics B.V. • 10.Amicus Therapeutics GmbH ...
IRS number
200422823
FOLD stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
9 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
8 Jan 24
Transcripts
FOLD
Earnings call transcript
2024 Q1
9 May 24
FOLD
Earnings call transcript
2023 Q4
28 Feb 24
FOLD
Earnings call transcript
2023 Q3
8 Nov 23
FOLD
Earnings call transcript
2023 Q2
8 Aug 23
FOLD
Earnings call transcript
2023 Q1
10 May 23
FOLD
Earnings call transcript
2022 Q4
1 Mar 23
FOLD
Earnings call transcript
2022 Q3
7 Nov 22
FOLD
Earnings call transcript
2022 Q2
5 Aug 22
FOLD
Earnings call transcript
2022 Q1
9 May 22
FOLD
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
4
Bradley L Campbell
9 Jul 24
4
Bradley L Campbell
3 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
4
BURKE W WHITMAN
7 Jun 24
4
CRAIG A WHEELER
7 Jun 24
4
EIRY ROBERTS
7 Jun 24
4
Lynn Dorsey Bleil
7 Jun 24
4
Michael Aaron Kelly
7 Jun 24
4
GLENN SBLENDORIO
7 Jun 24
4
MICHAEL RAAB
7 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 212.79 mm | 212.79 mm | 212.79 mm | 212.79 mm | 212.79 mm | 212.79 mm |
Cash burn (monthly) | 12.43 mm | (no burn) | 14.53 mm | 11.71 mm | 9.90 mm | 6.73 mm |
Cash used (since last report) | 48.05 mm | n/a | 56.17 mm | 45.25 mm | 38.27 mm | 26.01 mm |
Cash remaining | 164.75 mm | n/a | 156.63 mm | 167.54 mm | 174.53 mm | 186.79 mm |
Runway (months of cash) | 13.3 | n/a | 10.8 | 14.3 | 17.6 | 27.8 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 238 |
Opened positions | 94 |
Closed positions | 16 |
Increased positions | 61 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 3.62 tn |
Total shares | 312.77 mm |
Total puts | 352.90 k |
Total calls | 841.20 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 28.20 mm | $332.25 bn |
Perceptive Advisors | 28.06 mm | $330.52 bn |
Avoro Capital Advisors | 27.40 mm | $322.77 bn |
BLK Blackrock | 22.85 mm | $269.17 bn |
Wellington Management | 18.80 mm | $221.51 bn |
JPM JPMorgan Chase & Co. | 15.69 mm | $184.84 bn |
JHG Janus Henderson | 13.81 mm | $162.71 bn |
Redmile | 13.26 mm | $156.17 bn |
STT State Street | 12.44 mm | $146.57 bn |
William Blair Investment Management | 11.53 mm | $135.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jul 24 | Bradley L Campbell | Common Stock | Sell | Dispose S | No | No | 10.0048 | 6,100 | 61.03 k | 886,654 |
5 Jul 24 | Bradley L Campbell | Common Stock | Option exercise | Acquire M | No | No | 8.61 | 6,100 | 52.52 k | 892,754 |
5 Jul 24 | Bradley L Campbell | Stock Options Common Stock | Option exercise | Dispose M | No | No | 8.61 | 6,100 | 52.52 k | 37,500 |
1 Jul 24 | Bradley L Campbell | Common Stock | Sell | Dispose S | No | No | 10.0021 | 1,400 | 14.00 k | 886,654 |
1 Jul 24 | Bradley L Campbell | Common Stock | Option exercise | Acquire M | No | No | 8.61 | 1,400 | 12.05 k | 888,054 |
1 Jul 24 | Bradley L Campbell | Stock Options Common Stock | Option exercise | Dispose M | No | No | 8.61 | 1,400 | 12.05 k | 43,600 |
6 Jun 24 | MCGLYNN Margaret G | Common Stock | Grant | Acquire A | No | No | 0 | 11,847 | 0.00 | 71,136 |
6 Jun 24 | MCGLYNN Margaret G | Stock Options Common Stock | Grant | Acquire A | No | No | 10.27 | 42,467 | 436.14 k | 42,467 |
6 Jun 24 | Michael Raab | Common Stock | Grant | Acquire A | No | No | 0 | 11,847 | 0.00 | 95,443 |
6 Jun 24 | Michael Raab | Stock Options Common Stock | Grant | Acquire A | No | No | 10.27 | 42,467 | 436.14 k | 42,467 |
News
Wells Fargo Initiates Coverage On Amicus Therapeutics with Overweight Rating, Announces Price Target of $18
30 May 24
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
14 May 24
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
14 May 24
Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
14 May 24
UBS Maintains Buy on Amicus Therapeutics, Lowers Price Target to $19
10 May 24
Press releases
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
4 Jun 24
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
9 May 24
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
8 May 24
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
1 May 24